QUALITATIVE RESEARCH IN HAEMOPHILIA A: EMICIZUMAB TRANSFORMS LIFESTYLE OF PATIENTS WITH INHIBITOR

被引：1
|
作者：
Lambert, T. [1 ]
Rothschild, C. [2 ]
Baillon, N. [3 ]
Gaudin, H. [4 ]
Acquadro, M. [5 ]
Arnould, B. [5 ]
Lambert, J. [5 ]
Negrier, C. [6 ]
机构：
[1] Hop Bicetre, AP HP, Le Kremlin Bicetre, France
[2] Hop Necker Enfants Malad, Paris, France
[3] Roche SAS, Boulogne, France
[4] Chugai Pharma France, Puteaux La Defense, France
[5] Mapi, Lyon, France
[6] CHU Lyon, HCL, Bron, France
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2921
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY223
引用
收藏
页码：S474 / S474
页数：1
相关论文
共 50 条
  • [1] QUALITATIVE RESEARCH EXPLORING LIFE CHANGES IN PATIENTS LIVING WITH SEVERE HAEMOPHILIA A WITHOUT INHIBITORS TREATED WITH EMICIZUMAB
    Volot, F.
    Lambert, T.
    Harroche, A.
    Derlon, A. B.
    Guerin, N.
    Castet, S.
    Hadim, F.
    Gaude, A.
    Tugaut, B.
    Michel, A. -S.
    Guillet, B.
    HAEMOPHILIA, 2023, 29 : 195 - 195
  • [2] Persistent inhibitor in acquired haemophilia A: A case for emicizumab?
    Ganslmeier, Mira
    Pekrul, Isabell
    Heinrich, Daniel Alexander
    Angstwurm, Matthias
    Spannagl, Michael
    Moehnle, Patrick
    HAEMOPHILIA, 2021, 27 (04) : E502 - E505
  • [3] Assessment of the budgetary impact of an emicizumab therapy introduction for patients with severe haemophilia A without inhibitor
    Oka, G.
    Pieragostini, R.
    Roussel-Robert, V.
    Paubel, P.
    Degrassat-Theas, A.
    Lopez, I.
    ANNALES PHARMACEUTIQUES FRANCAISES, 2023, 81 (03): : 529 - 537
  • [4] Uptake of emicizumab in PUPs with severe haemophilia A and changes in inhibitor incidence
    Fischer, K.
    Lassila, R.
    Peyvandi, F.
    Gatt, A.
    Gouw, S.
    Hollingworth, R.
    Lambert, T.
    Kaczmarek, R.
    Makris, M.
    HAEMOPHILIA, 2024, 30 : 100 - 101
  • [5] Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors
    Ebbert, Patrick T.
    Xavier, Frederico
    Seaman, Craig D.
    Ragni, Margaret V.
    HAEMOPHILIA, 2020, 26 (01) : 41 - 46
  • [6] Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A
    Holstein, Katharina
    Albisetti, Manuela
    Bidlingmaier, Christoph
    Halimeh, Susan
    Heine, Sabine
    Klamroth, Robert
    Koenigs, Christoph
    Kurnik, Karin
    Male, Christoph
    Oldenburg, Johannes
    Streif, Werner
    Wermes, Cornelia
    Escuriola-Ettingshausen, Carmen
    HAMOSTASEOLOGIE, 2020, 40 (05): : 561 - 571
  • [7] Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors
    Mahlangu, Johnny N.
    BIODRUGS, 2018, 32 (06) : 561 - 570
  • [8] Use of emicizumab in Venezuelan haemophilia A patients: Preliminary report
    Boadas, Apsara
    Ruiz-Saez, Arlette
    Aponte, Laura
    Echenagucia, Marion
    Lugo, Ines
    Tersek, Yraida
    HAEMOPHILIA, 2022, 28 : 51 - 52
  • [9] Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors
    Johnny N. Mahlangu
    BioDrugs, 2018, 32 : 561 - 570
  • [10] Major surgery in a patient with Haemophilia A with high responder inhibitor (INH) on Emicizumab (Emi)
    Brodard, J.
    Quarroz, C.
    Pavicic, M.
    Baumgartner, D.
    Sommerhalder, R.
    Siebenrock, K.
    Angelillo-Scherrer, A.
    Hovinga, J. A. Kremer
    SWISS MEDICAL WEEKLY, 2019, 149 : 35S - 35S
12345